The Biofactory, a biomedical incubator supported by Singapore Polytechnic, aims to create successful biomedical companies from Singapore-developed technologies. Recently, it has also been recognised as an incubator under the National Research Foundation’s Technology Incubation Scheme (TIS).
The Biofactory’s key objective is to create more product-owners by bringing more Singapore-developed biomedical technologies, spin-offs and start-ups to the market. Of four start-ups established, two have been launched internationally in 2011.
IPI assisted The Biofactory in its accelerator function by first analysing its innovation needs, identifying suitable technologies and developing a product-roadmap to meet its business goals. With a clear understanding of its needs and goals, IPI assessed and validated various potential technologies in order to select suitable ones. Working in synergy with IPI, The Biofactory has been able to identify promising biomedical technologies that can be commercialised into educational, research or diagnostic kits.
“IPI is a great resource in identifying and evaluating state-of-the-art technologies to meet our business challenges,” said Theodore Tan, Director of The Biofactory. “We are also very glad that IPI has provided project-planning assistance and linked us up with various technology partners and research collaborators to further enhance our R&D capability.”
IPI also worked closely with our technology partner Exploit Technologies Pte Ltd (ETPL) to facilitate technology transfer. As a result, The Biofactory has successfully signed an agreement with ETPL to in-license and develop its technology into an Educational and a Biotech Research kit. The products are expected to be launched in some time this year. It will also continue to work with a local research institute and Singapore Polytechnic to potentially develop this technology into a diagnostic kit.
Theodore Tan added, “Through IPI’s Technology Assessment service, we are able to identify suitable technologies more quickly and effectively and focus on commercialising these technologies at an accelerated pace. We certainly will work together with IPI again for future projects”
Sub Title
The Biofactory, a biomedical incubator supported by Singapore Polytechnic, accelerates the commercialisation of Singapore-developed biomedical technologies, with IPI Singapore playing a pivotal role in technology assessment and partnership facilitation.
Impact Title
Driving Commercial Success in Biomedical Innovation
Sub Title
Driving Commercial Success in Biomedical Innovation
Sub Heading
Accelerating biomedical innovation through strategic technology assessment.
At a glance
Health & Personal Care
Industry
Technology Assessment, Partnership Facilitation
IPI Service
Biomedical Innovation
Key Technology
Add Impact
With IPI Singapore’s support, The Biofactory was able to identify and commercialise promising biomedical technologies more quickly and effectively. The collaboration enabled the development of educational and research kits, with products launched internationally, demonstrating the success of the accelerated approach.
Accelerated Commercialisation
By linking The Biofactory with technology partners and research collaborators, IPI facilitated the transfer and development of cutting-edge technologies. This not only enhanced The Biofactory’s R&D capabilities but also positioned it to continue developing innovative solutions for the biomedical sector.
Strengthened R&D Capabilities
Sub Title
The Biofactory leveraged IPI Singapore’s expertise to identify, assess, and commercialise biomedical technologies, resulting in successful product launches and strengthened R&D capabilities.
How it happened
IPI began by engaging The Biofactory to understand its innovation needs and business goals. After conducting a thorough analysis, IPI identified and validated promising biomedical technologies suitable for commercialisation. IPI then facilitated introductions and collaborations with key technology partners such as ETPL, supporting the technology transfer process. This partnership led to successful in-licensing agreements and the development of new products, with ongoing collaborations to further expand The Biofactory’s product offerings.
The challenge
The Biofactory needed to identify biomedical technologies with strong commercial potential from a diverse pool of innovations. The challenge was to rigorously assess and select technologies that aligned with business goals and could be rapidly developed into market-ready products.
Technology Identification and Validation
Forming effective partnerships for technology transfer was critical for The Biofactory’s success. Navigating the complexities of in-licensing and collaborating with research institutions required strategic facilitation to ensure smooth and productive engagements.
Partnership and Technology Transfer
The challenges title
The Challenge
The challenges description
The Biofactory’s primary objective was to increase the number of successful product-owners by bringing more Singapore-developed biomedical technologies, spin-offs, and start-ups to the market. However, the journey from technology development to commercialisation in the biomedical sector is fraught with challenges. Identifying promising technologies that are both innovative and commercially viable requires deep domain expertise, rigorous assessment, and access to a network of research and industry partners.
With only four start-ups established and a goal to expand their impact, The Biofactory faced the challenge of sourcing and validating technologies that could be rapidly developed into market-ready products. The process of evaluating potential technologies, aligning them with business goals, and ensuring they could be commercialised into educational, research, or diagnostic kits demanded a strategic approach. Additionally, forming the right partnerships for technology transfer and development was essential to accelerate time-to-market and ensure successful product launches.
The Solution Title
The Solution
The Solution Description
IPI Singapore supported The Biofactory’s accelerator function by first analysing its innovation needs, identifying suitable technologies, and developing a product roadmap aligned with its business objectives. IPI’s team worked closely with The Biofactory to gain a clear understanding of its goals and challenges, enabling a targeted approach to technology sourcing and assessment.
Through its Technology Assessment service, IPI assessed and validated various potential technologies, selecting those with the highest commercialisation potential. IPI also facilitated connections with technology partners and research collaborators, including Exploit Technologies Pte Ltd (ETPL), to enable effective technology transfer. This collaborative approach empowered The Biofactory to focus on commercialising selected technologies at an accelerated pace, resulting in agreements to in-license and develop new educational and research kits.
Testimonial Section
Testimonial title
Client Perspective
Testimonial description
"IPI is a great resource in identifying and evaluating state-of-the-art technologies to meet our business challenges."
Testimonial Name
Theodore Tan
Testimonial Designation
Director, The Biofactory
Testimonial title
Client Perspective
Testimonial description
"Through IPI’s Technology Assessment service, we are able to identify suitable technologies more quickly and effectively and focus on commercialising these technologies at an accelerated pace. We certainly will work together with IPI again for future projects"
Testimonial Name
Theodore Tan
Testimonial Designation
Director, The Biofactory
Business impact Heading
Business Impact
Business impact title
Accelerated commercialisation and expanded product portfolio
Impact scores
Counter Text
Start-ups Established
Counter Text
International Launches
Counter Text
Technology Partnerships
Overview
The Biofactory is a biomedical incubator supported by Singapore Polytechnic, dedicated to creating successful biomedical companies from Singapore-developed technologies. Recognised as an incubator under the National Research Foundation’s Technology Incubation Scheme (TIS), The Biofactory focuses on nurturing spin-offs and start-ups to bring innovative biomedical solutions to market.
Slug
hatching-new-biomedical-innovations
